Search

Your search keyword '"SKAISTE TULYTE"' showing total 5 results
Start Over Author "SKAISTE TULYTE"
5 results on '"SKAISTE TULYTE"'

1. Colorectal Neoplasm with Predominant Neuroendocrine Immunophenotype: Where does Adenocarcinoma End?

Author

Gabrielė Cibulskaitė, Rokas Stulpinas, Eligijus Poškus, Skaistė Tulytė, and Ugnius Mickys

Subjects
mixed neuroendocrine non-neuroendocrine neoplasm, MiNEN, mixed adeno-neuroendocrine carcinoma MANEC, large cell neuroendocrine carcinoma, colorectal neoplasm, Surgery, RD1-811
Abstract

MiNEN (mixed neuroendocrine-non-neuroendocrine neoplasm) is described in the 5th edition WHO classification of tumors of the digestive system as a mixed neoplasm, composed of neuroendocrine and non-neuroendocrine parts, each accounting for at least 30% of the tumor. Recently this formal criterion has been criticized based on the theory that both of these components could have a monoclonal origin and non-neuroendocrine cells develop neuroendocrinicity in the later evolutionary steps of adenocarcinoma. For this reason, the identification of pure adenocarcinoma component, that was overgrown by a more aggressive clone with neuroendocrine features, in a pathological specimen can be difficult and, in some cases, even impossible. So, it is likely that at least some of large cell neuroendocrine carcinomas follow the same pathway, a theory that is further supported by adenocarcinoma-like molecular alterations in these tumors. Precise diagnosis (which means identifying and naming each tumor component regardless of its size) is essential for a personalized treatment strategy. We present an illustrative case of a rectal neoplasm that could be classified as a poorly differentiated neuroendocrine carcinoma, but exhibits morphological heterogeneity, mucin production and has a typical KRAS mutation pointing to adenocarcinomatous origin, which makes MiNEN a more accurate diagnosis. The article discusses the key points in classification, pathogenesis, and diagnostic approach to help effectively manage such neoplasms.

Published
2022
Full Text
View/download PDF

2. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) with cisplatin and doxorubicin in combination with FOLFOX chemotherapy as a first-line treatment for gastric cancer patients with peritoneal metastases: single-arm phase II study

Author

Martynas Luksta, Augustinas Bausys, Klaudija Bickaite, Rokas Rackauskas, Marius Paskonis, Raminta Luksaite-Lukste, Anastasija Ranceva, Rokas Stulpinas, Birute Brasiuniene, Edita Baltruskeviciene, Nadezda Lachej, Rasa Sabaliauskaite, Rimantas Bausys, Skaiste Tulyte, and Kestutis Strupas

Subjects
Gastric cancer, Peritoneal metastases, PIPAC, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Abstract Background Gastric cancer (GC) remains among the most common and most lethal cancers worldwide. Peritoneum is the most common site for distant dissemination. Standard treatment for GC peritoneal metastases (PM) is a systemic therapy, but treatment outcomes remain very poor, with median overall survival ranging between 3-9 months. Thus, novel treatment methods are necessary. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) is the most novel technique for intraperitoneal chemotherapy. Some preliminary data suggest PIPAC can achieve improved long-term outcomes in patients with GC PM, especially when used in combination with systemic chemotherapy. However, there is a lack of data from well-design prospective studies that would confirm the efficacy of PIPAC and systemic therapy combination for first-line treatment. Methods This study is an investigator-initiated single-arm, phase II trial to investigate the efficacy of PIPAC combined with systemic FOLFOX (5-fluorouracil, oxaliplatin, leucovorin) as a first-line treatment for GC PM. The study is conducted in 2 specialized GC treatment centers in Lithuania. It enrolls GC patients with histologically confirmed PM without prior treatment. The treatment protocol consists of PIPAC with cisplatin (10.5 mg/m2 body surface in 150 mL NaCl 0.9%) and doxorubicin (2.1 mg/m2 in 50 mL NaCl 0.9%) followed by 2 cycles of FOLFOX every 6–7 weeks. In total 3 PIPACs and 6 cycles of FOLFOX will be utilized. The primary outcome of the study is the objective response rate (ORR) according to RECIST v. 1.1 criteria (Eisenhauer et al., Eur J Cancer 45:228–47) in a CT scan performed 7 days after the 4th cycle of FOLFOX. Secondary outcomes include ORR after all experimental treatment, PIPAC characteristics, postoperative morbidity, histological and biochemical response, ascites volume, quality of life, overall survival, and toxicity. Discussion This study aims to assess PIPAC and FOLFOX combination efficacy for previously untreated GC patients with PM. Trial registration NCT05644249. Registered on December 9, 2022.

Published
2023
Full Text
View/download PDF

3. The Effects of Treatment on Peripheral Blood Immune Cell Profile in Pancreatic Ductal Adenocarcinoma (PDAC)

Author

SKAISTE TULYTE, DAINIUS CHARACIEJUS, REDA MATUZEVICIENE, AUSRA JANIULIONIENE, MANTAS RADZEVICIUS, TADAS ZVIRBLIS, and AUDRIUS SILEIKIS

Subjects
Killer Cells, Natural, Pancreatic Neoplasms, Cancer Research, Oncology, T-Lymphocyte Subsets, Humans, General Medicine, Carcinoma, Pancreatic Ductal
Abstract

This study evaluated whether circulating lymphocytes, assessed by flow cytometry, is a prognostic biomarker in pancreatic ductal adenocarcinoma (PDAC).We studied T cell subsets in blood samples from a cohort of 41 patients diagnosed with PDAC. Patients underwent surgery of the primary site and adjuvant chemotherapy or were treated with 1A decline in CD19+ B lymphocytes, natural killer (NK) cells CD3-CD56+CD16+, and T regulatory cells CD4+FOXP3+ during treatment was observed. NKT-like cells CD3+CD56+ and cytotoxic T cells CD3+CD8+ tended to increase after two months and decrease after that.Statistically significant changes in lymphocyte counts in peripheral blood were detected in patients with PDAC during treatment.

Published
2022
Full Text
View/download PDF

4. Dabrafenib plus trametinib is effective in the treatment of BRAF V600-mutated metastatic melanoma patients

Author

Massimo Aglietta, Delvys Rodriguez-Abreu, Georgina V. Long, Pier Francesco Ferrucci, Dara Stein, Brianna King, Alexandr Poprach, Victoria Atkinson, Shahneen Sandhu, Philippe Legenne, Alvydas Česas, Virtudes Soriano, Egbert de Jong, Skaiste Tulyte, Gian Carlo Antonini Cappellini, Geke A. P. Hospers, Johannes V. Van Thienen, Sayed Ali, Mike Lau, and Guided Treatment in Optimal Selected Cancer Patients (GUTS)

Subjects
Compassionate Use Trials, Male, 0301 basic medicine, Oncology, Dabrafenib plus trametinib, Cancer Research, Skin Neoplasms, MONOTHERAPY, MULTICENTER, 0302 clinical medicine, Antineoplastic Combined Chemotherapy Protocols, Oximes, BRAF V600-mutated, Stage (cooking), MB, Trametinib, trametinib, Melanoma, Imidazoles, Middle Aged, OPEN-LABEL, MEK, 3. Good health, Treatment Outcome, Tolerability, 030220 oncology & carcinogenesis, SAFETY, SURVIVAL, Female, chart review, medicine.drug, Adult, Proto-Oncogene Proteins B-raf, medicine.medical_specialty, Combination therapy, Pyridones, Ipilimumab, Pyrimidinones, Dermatology, Disease-Free Survival, BRAF, 03 medical and health sciences, Internal medicine, medicine, melanoma, Humans, Dabrafenib plus trametinib, BRAF V600-mutated, metastatic melanoma DESCRIBE II, dabrafenib, MEK INHIBITION, Retrospective Studies, business.industry, IPILIMUMAB, Dabrafenib, medicine.disease, MUTANT MELANOMA, Clinical trial, 030104 developmental biology, metastatic melanoma DESCRIBE II, business
Abstract

In clinical trials, dabrafenib plus trametinib improved overall survival (OS) compared with single-agent BRAF inhibitors (BRAFi) in patients with BRAF V600-mutant unresectable or metastatic melanoma. We investigated dabrafenib plus trametinib therapy in a compassionate-use setting [Named Patient Program (NPP); DESCRIBE II]. A retrospective chart review of patients with BRAF V600-mutated unresectable stage III/IV melanoma receiving dabrafenib plus trametinib as compassionate use was conducted. Treatment patterns and duration, clinical outcomes, and tolerability were evaluated. Of 271 patients, 92.6% had stage IV melanoma, including 36.5% with brain metastases. Overall, 162 patients (59.8%) were BRAFi naive and 171 (63.1%) received first-line dabrafenib plus trametinib. Among BRAFi-naive patients, the overall response rate (ORR) was 67.3%, median OS (mOS) was 20.0 months, and median progression-free survival (mPFS) was 7.5 months. In BRAFi-naive patients with known brain metastases (n = 62), ORR was 61.3%, mOS was 15.5 months, and mPFS was 6.2 months. Eighty-four patients received BRAFi monotherapy for >30 days and switched to dabrafenib plus trametinib prior to progression. Of these 84 patients, 63 had known disease status at the time of switch, and 22 improved with the combination therapy. No new safety signals were identified, and dabrafenib plus trametinib was well tolerated. Dabrafenib plus trametinib showed substantial clinical activity in NPP patients with BRAF V600-mutated unresectable or metastatic melanoma. Analysis of treatment patterns demonstrated the effectiveness of the combination in patients with brain metastases and across lines of therapy with a well tolerated and manageable safety profile.

Published
2020
Full Text
View/download PDF

5. A Retrospective Analysis of Dabrafenib and/or Dabrafenib Plus Trametinib Combination in Patients with Metastatic Melanoma to Characterize Patients with Long-Term Benefit in the Individual Patient Program (DESCRIBE III)

Author

Michele Del Vecchio, Hiya Banerjee, Massimo Aglietta, Pier Francesco Ferrucci, Helen Gogas, Teddy Saliba, Roberta Depenni, Egbert de Jong, Pietro Quaglino, Francesca Consoli, Ana Arance, Skaiste Tulyte, Dimitrios Bafaloukos, Bart Neyns, Victoria Atkinson, Ivana Krajsová, Rossana Gueli, Paolo A. Ascierto, Clinical sciences, Medical Oncology, Laboratory of Molecular and Medical Oncology, and Laboratory of Molecullar and Cellular Therapy

Subjects
Oncology, Cancer Research, medicine.medical_specialty, real-world, BRAF V600, Chart review, Dabrafenib, Melanoma, Real-world, Trametinib, Metastatic melanoma, Combination therapy, chart review, dabrafenib, melanoma, trametinib, Article, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, Medicine, In patient, 030212 general & internal medicine, RC254-282, business.industry, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, medicine.disease, 030220 oncology & carcinogenesis, Observational study, business, medicine.drug
Abstract

The dabrafenib plus trametinib (dab + tram) combination has demonstrated durable long-term efficacy in patients with BRAF V600–mutant metastatic melanoma. However, real-world data characterizing patients with long-term benefit are limited. DESCRIBE III was a global, observational, retrospective, chart review study in patients with unresectable or metastatic melanoma treated with dab monotherapy and/or dab + tram combination therapy as part of the Named Patient Program or Individual Patient Program. Overall, 509 patients were enrolled. Patients were categorized into three groups based on their observed treatment duration: long-term (on therapy ≥12 months), intermediate (on therapy ≥6 months and &lt, 12 months), and short-term (on therapy &lt, 6 months) duration of benefit. More patients in the short-term duration of benefit group had baseline characteristics associated with poor prognosis compared with the other two groups. Median lactate dehydrogenase (LDH) levels (368 U/L) at baseline were also higher in the short-term duration of benefit group. No new safety signals were identified. DESCRIBE III identified baseline characteristics associated with long-term benefit of dab + tram. Lower LDH level and &lt, 3 metastatic sites at baseline were associated with a longer duration of benefit, confirming that the findings from COMBI-d and COMBI-v are relevant to patients treated in a real-world setting.

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results